113 related articles for article (PubMed ID: 19726982)
21. HSV therapy and HIV-1 reduction.
Martinez V; Caumes E
N Engl J Med; 2007 May; 356(22):2323; author reply 2324. PubMed ID: 17538093
[No Abstract] [Full Text] [Related]
22. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
23. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients.
Kim JH; Schaenman JM; Ho DY; Brown JM
Biol Blood Marrow Transplant; 2011 Feb; 17(2):259-64. PubMed ID: 20615475
[TBL] [Abstract][Full Text] [Related]
24. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Vanpouille C; Lisco A; Introini A; Grivel JC; Munawwar A; Merbah M; Schinazi RF; Derudas M; McGuigan C; Balzarini J; Margolis L
Antimicrob Agents Chemother; 2012 May; 56(5):2604-11. PubMed ID: 22314523
[TBL] [Abstract][Full Text] [Related]
25. Recalcitrant pseudotumoral anogenital herpes simplex virus type 2 in HIV-infected patients: evidence for predominant B-lymphoplasmocytic infiltration and immunomodulators as effective therapeutic strategy.
Sbidian E; Battistella M; Legoff J; Lafaurie M; Bézier M; Agbalika F; Simon F; Bouscarat F; Cayuela JM; Carcelain G; Houhou N; Bagot M; Molina JM; Janier M; Bachelez H
Clin Infect Dis; 2013 Dec; 57(11):1648-55. PubMed ID: 24065320
[TBL] [Abstract][Full Text] [Related]
26. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France.
Frobert E; Burrel S; Ducastelle-Lepretre S; Billaud G; Ader F; Casalegno JS; Nave V; Boutolleau D; Michallet M; Lina B; Morfin F
Antiviral Res; 2014 Nov; 111():36-41. PubMed ID: 25218782
[TBL] [Abstract][Full Text] [Related]
27. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.
Tanton C; Weiss HA; Rusizoka M; Legoff J; Changalucha J; Baisley K; Mugeye K; Everett D; Belec L; Clayton TC; Ross DA; Hayes RJ; Watson-Jones D
J Infect Dis; 2010 May; 201(9):1285-97. PubMed ID: 20235836
[TBL] [Abstract][Full Text] [Related]
28. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.
Sauerbrei A; Bohn K; Heim A; Hofmann J; Weissbrich B; Schnitzler P; Hoffmann D; Zell R; Jahn G; Wutzler P; Hamprecht K
Antivir Ther; 2011; 16(8):1297-308. PubMed ID: 22155911
[TBL] [Abstract][Full Text] [Related]
29. [Virostatic treatment of herpes simplex infections of variable severity].
Raab R; Söltz-Szöts J
Hautarzt; 1990 Aug; 41(8):413-5. PubMed ID: 2272824
[TBL] [Abstract][Full Text] [Related]
30. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
[TBL] [Abstract][Full Text] [Related]
31. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients.
van Velzen M; Missotten T; van Loenen FB; Meesters RJ; Luider TM; Baarsma GS; Osterhaus AD; Verjans GM
J Clin Virol; 2013 Jul; 57(3):215-21. PubMed ID: 23582986
[TBL] [Abstract][Full Text] [Related]
32. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
[TBL] [Abstract][Full Text] [Related]
33. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.
Corey L; Wald A; Celum CL; Quinn TC
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):435-45. PubMed ID: 15021308
[TBL] [Abstract][Full Text] [Related]
34. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.
Paz-Bailey G; Sternberg M; Puren AJ; Markowitz LE; Ballard R; Delany S; Hawkes S; Nwanyanwu O; Ryan C; Lewis DA
J Infect Dis; 2009 Oct; 200(7):1039-49. PubMed ID: 19715417
[TBL] [Abstract][Full Text] [Related]
35. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.
Schuhmacher A; Reichling J; Schnitzler P
Phytomedicine; 2003; 10(6-7):504-10. PubMed ID: 13678235
[TBL] [Abstract][Full Text] [Related]
36. Herpes simplex virus infection, Acyclovir and IVIG treatment all independently cause gut dysbiosis.
Ramakrishna C; Mendonca S; Ruegger PM; Kim JH; Borneman J; Cantin EM
PLoS One; 2020; 15(8):e0237189. PubMed ID: 32760124
[TBL] [Abstract][Full Text] [Related]
37. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
Gray R; Wilson D
N Engl J Med; 2010 May; 362(18):1740; author reply 1741-2. PubMed ID: 20445189
[No Abstract] [Full Text] [Related]
38. Herpes simplex and HIV infections and preterm PROM.
Ehsanipoor RM; Major CA
Clin Obstet Gynecol; 2011 Jun; 54(2):330-6. PubMed ID: 21508703
[TBL] [Abstract][Full Text] [Related]
39. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus.
Shimada Y; Suzuki M; Shirasaki F; Saito E; Sogo K; Hasegawa M; Takehara K; Phromjai J; Chuhjo T; Shiraki K
J Med Virol; 2007 Nov; 79(11):1731-40. PubMed ID: 17854045
[TBL] [Abstract][Full Text] [Related]
40. Development of an aciclovir implant for the effective long-term control of herpes simplex virus type-1 infection in Vero cells and in experimentally infected SKH-1 mice.
Johnson TP; Frey R; Modugno M; Brennan TP; Margulies BJ
Int J Antimicrob Agents; 2007 Nov; 30(5):428-35. PubMed ID: 17851051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
